格隆汇5月12日|默沙东宣布,其新型碳青霉烯/酶抑制剂复合制剂锐可博(注射用亚胺西瑞)已正式在中国境内上市,适用于治疗18岁及以上患者由敏感革兰阴性菌引起的下列感染:医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎(HABP/VABP);治疗药物选择有限或无替代治疗的复杂性尿路感染(cUTI)(包括肾盂肾炎);治疗药物选择有限或无替代治疗的复杂性腹腔内感染(cIAI)。据悉,首批药物已在默沙东中国杭州...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.